Want to see PRME full AI Analyst Report?

Prime Medicine, Inc. (PRME) Price & Analysis

886 Followers

PRME Stock Chart & Stats

$3.81

-$0.14(-4.27%)

At close: Jan 08 4:00 PM EST

$3.81

-$0.14(-4.27%)

Day’s Range― - ―

52-Week Range$2.02 - $6.94

Previous CloseN/A

Volume144.88K

Average Volume (3M)2.91M

Market Cap

$698.99M

Enterprise Value$621.16M

Total Cash (Recent Filing)$135.50M

Total Debt (Recent Filing)$114.51M

Price to Earnings (P/E)―

Beta2.82

Next Earnings

Aug 06, 2026

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding180,617,450

10 Day Avg. Volume2,883,124

30 Day Avg. Volume2,909,180

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)4.27

Price to Sales (P/S)111.44

P/FCF Ratio-3.09

Enterprise Value/Market Cap0.89

Enterprise Value/Revenue153.98

Enterprise Value/Gross Profit-14.22

Enterprise Value/Ebitda-3.25

Forecast

1Y Price Target

$7.83

Price Target Upside105.60% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-1

Revenue Forecast (FY)$12.83M

Bulls Say, Bears Say

Bulls Say

Proprietary Prime Editing PlatformA proprietary prime editing platform is a durable competitive asset: it creates a technology moat and repeated application across multiple disease targets (liver, blood, etc.). Platform-based R&D supports long-term pipeline scalability and potential recurring licensing or royalty income if clinical success follows.

Collaboration And Licensing Revenue ModelReliance on collaborations and licensing provides non-dilutive funding streams and milestone-driven capital that can extend runway without immediate product sales. This model supports continued R&D investment and aligns incentives with partners, offering sustainable funding optionality over months to years.

Experienced CFO And Governance ContinuityAdding a veteran biotech finance executive and reaffirming directors/auditor strengthens financial governance and strategic oversight. Clear separation of CFO from CEO improves financial control and credibility with investors and partners, reducing execution risk on funding and partnerships over the medium term.

Bears Say

Rising Leverage And Shrinking EquityHigher leverage and falling equity reduce financial flexibility for an R&D-stage biotech that depends on external funding. Elevated debt magnifies refinancing and covenant risk, constraining strategic options and increasing dilution or costly financing likelihood if clinical progress or partner funding slows.

Weak Cash Generation And High Burn RateConsistent large operating and free-cash outflows indicate the company is burning cash to fund R&D. Persistent negative cash generation shortens runway absent new deals or financing, elevating reliance on milestone payments or capital raises that can dilute shareholders and disrupt long-term program continuity.

Declining Revenue And Deeply Negative MarginsFalling revenue alongside outsized operating losses shows the cost base is far ahead of commercialization scale. Structural negative margins increase dependence on external funding and indicate the company has not yet converted R&D into sustainable commercial cash flows, heightening execution and financing risk.

Prime Medicine, Inc. News

Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Prime Medicine (PRME) to Buy from Neutral with an $8 price target after the company...

7d ago

PRME

Prime Medicine granted RMAT designation for PM359

Prime Medicine (PRME) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to PM359,...

14d ago

PRME

Prime Medicine announces New Zealand cleared trial application for PM577a

Prime Medicine (PRME) announced that the New Zealand Medicines and Medical Devices Safety Authority has cleared the Company’s...

18d ago

PRME

CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CYTK) ), ( ($PRME) ), ( ($DOCS) ), ( ($WBD)...

2d ago

WBD

CYTK

Prime Medicine Stockholders Reaffirm Board and Auditor Choices

Prime Medicine, Inc. ( ($PRME) ) has shared an update. On June 5, 2026, Prime Medicine, Inc. held...

28d ago

PRME

Prime Medicine reports Q1 EPS (28c), consensus (25c)

Reports Q1 revenue $856,000, consensus $844,220. “Prime Medicine (PRME) continues to execute with clear momentum and a focused...

2M ago

PRME

Prime Medicine management to meet with Oppenheimer

Meeting to be held on May 11 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

2M ago

PRME

Prime Medicine Appoints Svetlana Makhni as New CFO

The latest announcement is out from Prime Medicine, Inc. ( ($PRME) ). On April 7, 2026, Prime Medicine’s...

3M ago

PRME

Prime Medicine appoints Makhni as Chief Financial Officer

Prime Medicine (PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer, CFO. Ms. Makhni will oversee...

3M ago

PRME

Prime Medicine: Prime Editing Platform and PM577 Create Compelling Risk‑Reward in Addressing Unmet Need in Wilson’s Disease

Prime Medicine, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville,...

3M ago

PRME

Oppenheimer bullish on Prime Medicine, initiates with an Outperform

As previously reported, Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target...

4M ago

PRME

Prime Medicine initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target Published first on...

4M ago

PRME

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: LASER PHOTONICS CORPORATION (LASE)...

4M ago

IRE

Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline

Prime Medicine, Inc. ( ($PRME) ) has issued an update. On March 3, 2026, Prime Medicine reported full-year...

4M ago

PRME

PRME FAQ

What was Prime Medicine, Inc.’s price range in the past 12 months?

Prime Medicine, Inc. lowest stock price was $2.02 and its highest was $6.94 in the past 12 months.

What is Prime Medicine, Inc.’s market cap?

Prime Medicine, Inc.’s market cap is $698.99M.

When is Prime Medicine, Inc.’s upcoming earnings report date?

Prime Medicine, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.

How were Prime Medicine, Inc.’s earnings last quarter?

Prime Medicine, Inc. released its earnings results on May 07, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.029.

Is Prime Medicine, Inc. overvalued?

According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prime Medicine, Inc. pay dividends?

Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here

What is Prime Medicine, Inc.’s EPS estimate?

Prime Medicine, Inc.’s EPS estimate is -0.26.

How many shares outstanding does Prime Medicine, Inc. have?

Prime Medicine, Inc. has 180,617,450 shares outstanding.

What happened to Prime Medicine, Inc.’s price movement after its last earnings report?

Prime Medicine, Inc. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -8.651%.

Which hedge fund is a major shareholder of Prime Medicine, Inc.?

Currently, no hedge funds are holding shares in PRME

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Prime Medicine, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-188.82%

Trailing 12-Months

Asset Growth

-10.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prime Medicine, Inc.

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Prime Medicine, Inc. (PRME) Earnings & Revenues

Historic Earnings Reports

PRME Stock 12 Month Forecast

Average Price Target

$7.83

▲(105.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.833333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.9846153846153847,4.569230769230769,5.153846153846153,5.738461538461538,6.323076923076922,6.907692307692307,7.492307692307692,8.076923076923077,8.661538461538461,9.246153846153845,9.83076923076923,10.415384615384614,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.741025641025641,4.082051282051282,4.423076923076923,4.764102564102564,5.105128205128205,5.446153846153846,5.787179487179487,6.128205128205128,6.469230769230769,6.810256410256411,7.151282051282051,7.492307692307692,{"y":7.833333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.523076923076923,3.646153846153846,3.769230769230769,3.8923076923076922,4.015384615384615,4.138461538461538,4.2615384615384615,4.384615384615385,4.507692307692308,4.63076923076923,4.753846153846154,4.876923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >